A possible role of endogenous central corticotrophin releasing factor in lipopolysaccharide induced thymic involution and cell apoptosis: effect of peripheral injection of corticotrophin releasing factor

Journal of Neuroimmunology
Meenal P Ullewar, Sudhir N Umathe

Abstract

The aim of the study was to investigate the role of endogenous peripheral and central corticotrophin-releasing factor (CRF) following lipopolysaccharide (LPS) challenge on thymic involution and apoptosis. Administration of LPS (100 μg/mouse, ip) led to thymic involution, to a decrease of CD4+CD8+ thymocyte subset, and to fragmentation of thymic DNA. Pretreatment of LPS challenged mice with intracerebroventricular α-helical CRF (a CRF antagonist) attenuated the effect of LPS however, intraventricular administered α-helical CRF failed to affect LPS response on thymus. Moreover, the effects of LPS on thymus, examined on 1, 7 and 14 days were wholly abrogated by prior administration of intraventricular CRF (10 μg/animal). The plasma corticosterone levels were found to be decreased with single dose of peripheral CRF in LPS challenged mice. These findings indicate that central endogenous CRF involved in LPS induced thymic atrophy. However, peripheral CRF offers protective effect on LPS induced thymic involution and cell apoptosis.

References

Jan 1, 1991·The Journal of Steroid Biochemistry and Molecular Biology·H O BesedovskyA Kabiersch
Apr 1, 1991·The Journal of Experimental Medicine·H R AlexanderJ A Norton
Feb 1, 1989·Endocrine Reviews·A BatemanS Solomon
May 1, 1994·Immunopharmacology and Immunotoxicology·D M KelleyS M Dubinett
Oct 29, 1993·Annals of the New York Academy of Sciences·M Irwin
Jan 14, 1997·European Journal of Pharmacology·S G CorreaI D Bianco
Jun 18, 1998·Annals of the New York Academy of Sciences·E L WebsterG P Chrousos
Jun 18, 1998·Annals of the New York Academy of Sciences·S M McCannV Rettori
Feb 28, 2002·Life Sciences·Blazej ZbytekJolanta Mysliwska
Oct 2, 2002·Shock·Colm PowerH Paul Redmond
Jan 23, 2003·International Immunopharmacology·Víctor Manuel VíctorMónica De la Fuente
Dec 24, 2004·Current Opinion in Critical Care·Albertus Beishuizen, Lambertus G Thijs
Nov 28, 2006·Frontiers in Bioscience : a Journal and Virtual Library·Sophia KalantaridouGeorge P Chrousos
Dec 21, 2006·International Immunopharmacology·James E TalmadgeBela Toth
Dec 21, 2006·International Immunopharmacology·Adel A GomaaEsraa A Ahmed

❮ Previous
Next ❯

Citations

Jan 29, 2016·Journal of Cellular and Molecular Medicine·Selene Pérez-GarcíaYasmina Juarranz
Mar 24, 2017·Archivum Immunologiae Et Therapiae Experimentalis·Abdur Rahman Ansari, Huazhen Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis